Technical Analysis for HURA - TuHURA Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 8.94% | |
| Below Lower BB | Weakness | 8.94% | |
| Down 3 Days in a Row | Weakness | 8.94% | |
| Down 4 Days in a Row | Weakness | 8.94% |
| Alert | Time |
|---|---|
| Up 10% | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Up 5% | about 17 hours ago |
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/09/2024
TuHURA Biosciences, Inc. Description
TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced Merkel Cell Carcinoma. In addition, TuHURA is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immune System Immunotherapy Tumor Cancer Immunotherapy Antineoplastic Drugs Checkpoint Inhibitor Tumor Microenvironment Pembrolizumab Adjunctive Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.3635 |
| 52 Week Low | 2.835 |
| Average Volume | 111,894 |
| 200-Day Moving Average | 6.02 |
| 50-Day Moving Average | 5.80 |
| 20-Day Moving Average | 4.88 |
| 10-Day Moving Average | 4.45 |
| Average True Range | 0.66 |
| RSI (14) | 26.47 |
| ADX | 42.45 |
| +DI | 7.99 |
| -DI | 38.57 |
| Chandelier Exit (Long, 3 ATRs) | 4.22 |
| Chandelier Exit (Short, 3 ATRs) | 4.90 |
| Upper Bollinger Bands | 6.46 |
| Lower Bollinger Band | 3.29 |
| Percent B (%b) | 0.0 |
| BandWidth | 64.97 |
| MACD Line | -0.64 |
| MACD Signal Line | -0.46 |
| MACD Histogram | -0.1852 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.91 | ||||
| Resistance 3 (R3) | 3.86 | 3.61 | 3.80 | ||
| Resistance 2 (R2) | 3.61 | 3.45 | 3.63 | 3.77 | |
| Resistance 1 (R1) | 3.45 | 3.36 | 3.53 | 3.50 | 3.73 |
| Pivot Point | 3.20 | 3.20 | 3.24 | 3.22 | 3.20 |
| Support 1 (S1) | 3.04 | 3.04 | 3.12 | 3.09 | 2.85 |
| Support 2 (S2) | 2.79 | 2.95 | 2.81 | 2.81 | |
| Support 3 (S3) | 2.63 | 2.79 | 2.78 | ||
| Support 4 (S4) | 2.68 |
